Spots Global Cancer Trial Database for Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

Official Title: Early Response Assessment Using on 3T Advanced MR Imaging as Predictor of Long-term Treatment Response in Newly Diagnosed Glioblastomas

Study ID: NCT02613988

Conditions

Adult Glioblastoma

Interventions

3 Tesla magnetic resonance imaging

Chemical exchange saturation transfer MRI

Diffusion weighted MRI

Dynamic susceptibility contrast MRI

Study Description

Brief Summary: This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.

Detailed Description: The standard care of patients with glioblastoma is concomitant chemoradiation and adjuvant temozolomide. Allowing for assessment of tumor therapy prior to treatment completion is important to select patients most likely to benefit from alternative treatment option. Multimodal advanced MR imaging- contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, chemical exchange saturation transfer imaging, and perfusion imaging on 3T enables quantitative assessment of treatment response. Quantifying changes in advanced MR imaging techniques would allow predict outcome for early and long-term treatment response and survival in glioblastomas.